Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 343, Issue 24, 2000, Pages 1750-1757

  Rai, Kanti R ^a,f   Peterson, Bercedis L ^a   Appelbaum, Frederick R ^b   Kolitz, Jonathan ^a   Elias, Laurence ^b   Shepherd, Lois ^c   Hines, John ^d   Threatte, Gregory A ^a   Larson, Richard A ^a   Cheson, Bruce D ^e   Schiffer, Charles A ^a  

^a Cancer and Leukemia Group B   (United States)

^b Southwest Oncology Group   (United States)

^c Queen's Cancer Research Institute   (Canada)

^d Eastern Cooperative Oncology Group   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTILEUKEMIC AGENT; CHLORAMBUCIL; FLUDARABINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPERINFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; VIDARABINE;

EID: 0034649696     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200012143432402     Document Type: Article

References (18)

1. Chlorambucil in indolent chronic lymphocytic leukemia
2. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia
3. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia
4. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia
5. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis
6. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
7. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
8. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
9. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia
10. Randomized clinical trial comparing two anthracyclin-containing regimens (CHOP and CAP) and fludarabine (FDR) in advanced chronic lymphocytic leukemia (CLL)
11. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: Preliminary results of a controlled clinical trial
12. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group
13. A critical analysis of staging in CLL
14. Clinical staging of chronic lymphocytic leukemia
15. Discrete sequential boundaries for clinical trials
16. Nonparametric estimation from incomplete observations
17. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
18. The impact of therapy with chlorambucil (C), fludarabine (F) or fludarabine + chlorambucil (F + C) on infections in patients with chronic lymphocytic leukemia (CLL): An intergroup study (CALGB9011)